Efficacy and safety of a new leuprolide acetate [leuprorelin] 3.75 mg depot formulation, GP-Pharm S.A., when given as palliative treatment to prostate cancer patients
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 Nov 2007 Status changed from in progress to completed.
- 22 Oct 2005 New trial record.